Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Riluzole for Treatment of Men With Methamphetamine Dependence: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Publisher Pubmed



Farahzadi MH1 ; Moazenzadeh E2 ; Razaghi E3 ; Zarrindast MR1 ; Bidaki R4 ; Akhondzadeh S2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Psychiatric Research Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Psychiatry, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Research Center of Addiction and Behavioral Sciences, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Source: Journal of Psychopharmacology Published:2019


Abstract

Background: Riluzole is a glutamate regulator and effective in treatment of neuropsychiatric conditions. Aims: We assessed riluzole for treatment of methamphetamine dependence. Methods: In this randomized, double-blind, placebo-controlled clinical trial, male outpatients with methamphetamine dependence who were 18–65 years old received either 50 mg riluzole (n=34) or placebo (n=54) twice daily for 12 weeks. Patients were excluded in case of comorbid serious medical conditions or neurologic disorders, comorbid psychiatric disorders other than methamphetamine dependence requiring specific treatment interventions, simultaneous positive urine test result for substances of abuse other than methamphetamine, smoking >3 days per week, simultaneous consumption of medications which are contraindicated or have interaction with riluzole. Results: Concerning primary outcomes, the cumulative mean number of attended weekly visits was higher in the riluzole arm compared with the placebo arm approaching a statistically significant difference (riluzole, median (range)=13.00 (2.00–13.00); placebo=4.00 (2.00–13.00); Mann-Whitney U=505.00, p-value=0.073), and the weekly measured rate of positive methamphetamine urine test results was significantly lower in the riluzole arm by the end of the study (riluzole=1 (5.00%), placebo=9 (45.00%), p-value=0.004). Patients in the riluzole arm experienced significantly greater improvement on all the craving, withdrawal, and depression measures regarding mean score changes from baseline to endpoint. No significant difference was detected between the two arms in terms of incidence of adverse events. Conclusion: Future randomized clinical trials are needed to investigate proper dosing strategy in a more inclusive sample. © The Author(s) 2018.
Related Docs
View other Related Docs
1. Riluzole Combination Therapy for Moderate-To-Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychiatric Research (2016)
2. Ketamine and Other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials, Iranian Journal of Psychiatry (2022)
3. Adding Extended-Release Methylphenidate to Psychological Intervention for Treatment of Methamphetamine Dependence: A Double-Blind Randomized Controlled Trial, Medical Journal of the Islamic Republic of Iran (2020)
4. Pexacerfont As a Crf1 Antagonist for the Treatment of Withdrawal Symptoms in Men With Heroin/Methamphetamine Dependence: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, International Clinical Psychopharmacology (2018)
5. Minocycline As Adjunctive Treatment to Risperidone in Children With Autistic Disorder: A Randomized, Double-Blind Placebo-Controlled Trial, Journal of Child and Adolescent Psychopharmacology (2016)
6. Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Psychiatry and Clinical Neurosciences (2016)
7. Review of Clinical Studies Targeting Inflammatory Pathways for Individuals With Autism, Frontiers in Psychiatry (2019)
8. N-Acetylcysteine As an Adjunctive Therapy to Risperidone for Treatment of Irritability in Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety, Clinical Neuropharmacology (2015)
Experts (# of related papers)
View all Related Experts
Shahin Akhondzadeh Basti (29)
Mohammad Reza Mohammadi (9)
Other Related Docs
9. Amantadine As Adjuvant Therapy in the Treatment of Moderate to Severe Obsessive–Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, Psychiatry and Clinical Neurosciences (2019)
10. Emerging Drugs for the Treatment of Irritability Associated With Autism Spectrum Disorder, Expert Opinion on Emerging Drugs (2024)
11. Minocycline Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2016)
12. Cilostazol Adjunctive Therapy in Treatment of Negative Symptoms in Chronic Schizophrenia: Randomized, Double-Blind, Placebo-Controlled Study, Human Psychopharmacology (2017)
13. Amantadine Reduces Persistent Fatigue During Post-Acute Withdrawal Phase in Methamphetamine Abstained Individuals: A Randomized Placebo-Controlled Trial, Journal of Substance Use (2018)
14. L-Carnosine As an Adjunctive Therapy to Risperidone in Children With Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Child and Adolescent Psychopharmacology (2018)
15. Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Journal of Clinical Pharmacy and Therapeutics (2017)
16. Glutamatergic Medications As Adjunctive Therapy for Moderate to Severe Obsessive-Compulsive Disorder in Adults: A Systematic Review and Meta-Analysis, BMC Pharmacology and Toxicology (2021)
17. Matrix Model As an Intensive Rehabilitation in Three Methadone Services in Iran, Iranian Rehabilitation Journal (2017)
18. Citicoline (Cdp-Choline) Add-On Therapy to Risperidone for Treatment of Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial, Human Psychopharmacology (2018)
19. Citicoline Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Clinical Neuropharmacology (2017)
20. Simvastatin As an Adjunctive Therapy to Risperidone in Treatment of Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Journal of Child and Adolescent Psychopharmacology (2018)
21. Sustained-Release Methylphenidate in Methamphetamine Dependence Treatment: A Double-Blind and Placebo-Controlled Trial, DARU# Journal of Pharmaceutical Sciences (2015)
22. L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2023)
23. L-Carnosine Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Affective Disorders (2020)
24. Electroconvulsive Therapy (Ect) and Aerobic Exercise Training (Aet) Increased Plasma Bdnf and Ameliorated Depressive Symptoms in Patients Suffering From Major Depressive Disorder, Journal of Psychiatric Research (2016)
25. Risperidone Combination Therapy With Propentofylline for Treatment of Irritability in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Clinical Neuropharmacology (2019)
26. Herbal Medicine in the Treatment of Obsessive Compulsive Disorder: A Review, Journal of Medicinal Plants (2019)
27. The Effects of Pioglitazone Adjuvant Therapy on Negative Symptoms of Patients With Chronic Schizophrenia: A Double-Blind and Placebo-Controlled Trial, Human Psychopharmacology (2016)
28. Cinnamomum Tamala As an Adjuvant Therapy in the Treatment of Major Depressive Disorder: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial With Placebo Control, Advances in Integrative Medicine (2020)
29. Palmitoylethanolamide As Adjunctive Therapy for Autism: Efficacy and Safety Results From a Randomized Controlled Trial, Journal of Psychiatric Research (2018)
30. Effect of Melissa Officinalis (Lemon Balm) on Sexual Dysfunction in Women: A Double- Blind, Randomized, Placebo-Controlled Study, Iranian Journal of Pharmaceutical Research (2018)
31. Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, Annals of Pharmacotherapy (2015)
32. L-Carnosine As an Adjuvant to Fluvoxamine in Treatment of Obsessive Compulsive Disorder: A Randomized Double-Blind Study, Human Psychopharmacology (2017)
33. A Pilot Double-Blind Placebo-Controlled Trial of Pioglitazone As Adjunctive Treatment to Risperidone: Effects on Aberrant Behavior in Children With Autism, Psychiatry Research (2015)
34. Patterns of Reduced Use and Abstinence in Multi-Site Randomized Controlled Trials of Pharmacotherapies for Cocaine and Methamphetamine Use Disorders, Drug and Alcohol Dependence (2021)
35. Resveratrol As Adjunctive Therapy in Treatment of Irritability in Children With Autism: A Double-Blind and Placebo-Controlled Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2020)
36. Sulforaphane As an Adjunctive Treatment for Irritability in Children With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Psychiatry and Clinical Neurosciences (2020)